# **Special Issue**

## **Melatonin in Cancer Treatment**

### Message from the Guest Editor

Melatonin (N-acetyl-5-methoxytryptamine) is a hormone synthesized and secreted mainly by the pineal gland in the dark, usually overnight. Melatonin acts as an oncostatic agent since it can modulate tumor gene expression, reducing the growth and development of estrogen-dependent breast tumors, mainly thanks to its antiestrogenic and antiangiogenic properties. As melatonin has no toxicity, this hormone is considered an excellent agent for use as a useful co-adjuvant in cancer prevention and therapy. Melatonin pharmacodynamics are based on its interactions with different receptors, such as MT-1, MT-2, calmodulin, or nuclear receptors.

This Special Issue aims to gather and display current knowledge and the newest findings about the use of melatonin in basic and translational cancer research. Here, we are interested in knowing the specific molecular changes induced by conventional therapies that melatonin can modulate in a potentially beneficial way. Updated research articles, short reports, integral reviews, and communications are welcome.

### **Guest Editor**

Dr. Javier Menéndez-Menéndez

Department of Physical and Analytical Chemistry, School of Chemistry, University of Oviedo, Oviedo, Spain

### Deadline for manuscript submissions

closed (10 August 2024)



## **Pharmaceuticals**

an Open Access Journal by MDPI

Impact Factor 4.8
CiteScore 7.7
Indexed in PubMed



## mdpi.com/si/180719

Pharmaceuticals
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
pharmaceuticals@mdpi.com

mdpi.com/journal/pharmaceuticals





## **Pharmaceuticals**

an Open Access Journal by MDPI

Impact Factor 4.8 CiteScore 7.7 Indexed in PubMed



## **About the Journal**

### Message from the Editor-in-Chief

Because of your expertise in the field of drug sciences, I kindly invite you to consider publishing your current work, in the form of a research article or a review, in the open access electronic journal *Pharmaceuticals*. *Pharmaceuticals* is characterized by an active editorial board and a dynamic editorial staff. Manuscripts are peer-reviewed and a final decision is provided to authors within 4–6 weeks after submission. Papers are published on the web immediately after acceptance. For details on the submission process or any other matter, please do not hesitate to contact us.

We hope to handle your contribution to *Pharmaceuticals* soon.

### Editor-in-Chief

### Prof. Dr. Amélia Pilar Rauter

Departamento de Química e Bioquímica (DQB) e Centro de Química Estrutural (CQE), Institute of Molecular Sciences, Faculdade de Cièncias, Universidade de Lisboa, Lisboa, Portugal

### **Author Benefits**

### Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

### **High Visibility:**

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

### Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)

